INTRODUCTION
The pathological activity of endometrial cells observed in adenomyosis leads to local and systemic immune and metabolic disorders.
PURPOSE
To study the possibilities of correcting immunological disorders in uterine endometriosis.
MATERIALS AND METHODS
78 patients with a diagnosis of uterine endometriosis of II—III degree, verified by ultrasound and hysteroscopic methods, were divided into 2 subgroups, one of them (32 women) received only Dienogest, and the second (46 patients) received a combination of Dienogest with Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic acid) and Cycloferon (Meglumine acridone acetate). Initially and 3 months after completion of the course of therapy, the immune (cytokine spectrum; components of the complement system; phagocytic activity of polymorphonuclear blood leukocytes) and metabolic status (activity of oxygen-dependent neutrophil systems; lipid peroxidation, antioxidant protection) were examined. Statistical processing of the results of the study was carried out according to the criteria of variance-statistical analysis with the calculation of mean values (M), arithmetic mean error (m) using the Microsoft Excel, 2010, Statistica 8 software package. Significance of differences was assessed by U-criterion. Differences with p<0.05 were considered statistically significant.
RESULTS
In uterine endometriosis, all 100% of the studied immune and metabolic parameters were changed, of which 40.3, 31.3 and 28.4% were with III, II and I degree disorders, respectively. A comprehensive analysis of the immune status and metabolic disorders in adenomyosis showed that after therapy with dienogest, 4.5% of parameters normalized, corrected — 61.2% and remained unchanged — 34.3%, and II and III degree of violations remained in 50.7% observations. Combination therapy leads to the normalization of 58.2% and the correction of 41.8% of the parameters of the immune status.
CONCLUSIONS
Sufficient clinical and laboratory efficacy of combination therapy substantiated the possibility of including drugs with immunomodulatory and antioxidant effects in the treatment of uterine endometriosis.
